Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
OSE Immunotherapeutics logo — Immuno-Oncology and Immuno-Inflammation - Breakthrough Immu...

OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients

Founded 2012 France France 76 employees Grant Total: $53.95M Biotechnology, Medical Devices +1

General Information

Company Name OSE Immunotherapeutics
Founded Year 2012
Location France France +2
Employees 76
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Grant
Social

Get notified when OSE Immunotherapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About OSE Immunotherapeutics

OSE Immunotherapeutics is an integrated biotech company founded in 2012, headquartered in France. The company focuses on developing first-in-class assets targeting cancer and inflammatory diseases. Its well-balanced first-in-class clinical pipeline includes promising products such as Tedopi® for non-small cell lung cancer (NSCLC) and OSE-279 in the advanced preclinical stage. OSE Immunotherapeutics has also formed partnerships with companies like Veloxis and Boehringer Ingelheim for the development of drugs in areas such as transplantation and advanced solid tumors. Moreover, the company aims to generate substantial value from its proprietary drug discovery platforms, namely BiCKI® focused on immuno-oncology and Myeloid platform targeting immuno-inflammation. Its most advanced BiCKI® candidate is targeting anti-PD1xIL-7, demonstrating its commitment to deliver next-generation first-in-class immunotherapeutics. OSE Immunotherapeutics recently received a €8.40M grant investment on April 10, 2024, with the backing of France 2030. With a strong focus on immuno-oncology and immuno-inflammation, the company shows great potential in addressing unmet medical needs in these critical therapeutic areas.

Taxonomy: biotech company, immunotherapy, cancer, inflammatory diseases, drug discovery, BiCKI platform, Myeloid platform, clinical pipeline, T-cell specific immunotherapy, CD47/SIRPα pathway, oncology research, immune system modulation, transplantation, clinical trials, cancer treatment

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 10 Apr 2024
Grant •••••• 2 •••• •••• 01 Aug 2023
Debt Financing •••••• 1 •••• •••• 09 Jul 2021
Funding Round •••••• - 23 May 2021
Grant •••••• 1
Investor
01 Dec 2020

View All 7 Funding Rounds

OSE Immunotherapeutics Alternatives & Competitors

OSE Immunotherapeutics vs
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. United States

Daring to create a world immune to cancer.

Post Ipo Equity
18 employees
Biotechnology, Health and Wellness
Compare OSE Immunotherapeutics vs Jounce Therapeutics, Inc.

FAQ About OSE Immunotherapeutics

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients
OSE Immunotherapeutics was founded in 2012.
OSE Immunotherapeutics is headquartered in France.
OSE Immunotherapeutics operates in the following industries: Biotechnology, Medical Devices, Pharmaceutical.
OSE Immunotherapeutics has approximately 76 employees.
OSE Immunotherapeutics has completed 7 funding rounds, raising a total of $53.95M. The latest funding stage is Grant.
Top alternatives and competitors to OSE Immunotherapeutics include Jounce Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OSE Immunotherapeutics and Jounce Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors OSE Immunotherapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy